Ro Partners with NovoCare® to Expand Wegovy® Access
Slice of Healthcare Team
Apr 30, 2025
Key Highlights
- Ro now offers all Wegovy® doses for $499/month via NovoCare® Pharmacy
- Direct access to FDA-approved GLP-1 medication through the Ro app
- Patients benefit from integrated telehealth, coaching, and pharmacy services
- Ro’s Body Membership supports holistic, ongoing obesity care
- Coverage verified through Ro Insurance Checker for lowest cost options
Source: Direct
Notable Quote
“ Fighting for patients means making it as easy and affordable as possible to access high-quality treatment, and that's exactly what integrating with NovoCare® Pharmacy offers patients. Adding Novo Nordisk's FDA-approved treatments at the best available cash price will help more patients nationwide get the obesity care they need to achieve their goals, particularly those without insurance coverage. ”
Zach Reitano, CEO and Co-founder at Ro
Why This Matters
This integration between Ro and NovoCare® Pharmacy marks a significant milestone in expanding access to affordable obesity care across the U.S. By offering all doses of Wegovy® at a flat $499 monthly cash price, Ro is making it simpler for patients—especially the uninsured—to receive FDA-approved GLP-1 medications without navigating traditional healthcare barriers. Combined with Ro’s comprehensive telehealth model and tools like the Insurance Checker, the partnership ensures broader, reliable, and transparent access to critical treatments for chronic conditions like obesity. This aligns with Ro’s mission to democratize healthcare through its vertically integrated platform, meeting patients where they are—at home.
